Direct-acting antivirals (DAAs) for HCV treatment have improved tolerance and efficacy among adults, but experience in vertical transmission is scarce. In our vertically HIV/HCV co-infected youth cohort of 58 patients, DAA achieved excellent rates of cure among naïve and pretreated individuals. Treating vertically infected seems important as 29.6% displayed advanced fibrosis at treatment initiation.
Keywords: HCV treatment; VIH/VHC co-infection; children and adolescents; direct-acting antivirals; vertical transmission.
© 2020 John Wiley & Sons Ltd.